Healthy and functional cells from discovery
We enable transformative therapies with our patent-pending continuous Flowfect™ cell engineering platforms. The non-viral Flowfect™ technology is a fast, scalable, and gentle process that yields billions of high-quality engineered cells in minutes while maintaining cell health and function.
KYTOPEN enables cell engineering from discovery to manufacturing
We are transforming cell engineering
The Flowfect™ technology combines continuous fluid flow with electric fields for high efficiency delivery of payloads such as mRNA, DNA, and CRISPR Cas9 RNP to primary cells. By carefully synchronizing the pulse delivery with the fluid flow we have eliminated the harmful effects of traditional transfection via static electroporation. Our ex vivo cell engineering platform is compatible with primary cells being developed for immuno-oncology and gene editing applications.
PRESERVED VIABILITY & FUNCTIONALITY
Our platform allows you to safely engineer your cells with minimal impact to their overall health and function. High-quality engineered cell products upfront will ultimate translate into faster cell therapy access for patients.
SCALABLE CELL ENGINEERING
The Flowfect™ platform combines proprietary electric fields and continuous fluid flow to engineer cells. We currently process billions of cells in minutes which makes our technology amenable to autologous and allogenic cell therapy applications. Our goal is to enable efficient and cost-effective manufacturing of cell therapies in days versus weeks.
We have fully automated cell engineering at the discovery scale. Whether you’re optimizing transfection conditions or discovering the next-generation cell therapy, Flowfect™ will accelerate your time to market.
KYTOPEN empowers your cells to flow from theory to therapy
Meet the team
KYTOPEN enables safer and faster therapeutic development
The intersection of innovation and opportunity
Kytopen is an MIT spinout with multiple publications in high-impact scientific journals.
KYTOPEN helps you discover efficiently
BioCentriq™ is a full service CDMO for cell and gene therapy process development and clinical manufacturing. Their GMP clinical manufacturing facility is in Newark, NJ with a pilot plant in South Brunswick. They manufacture autologous and allogeneic cell therapies and gene therapies and specialize in viral vector production, cell and viral banking, and upstream and downstream processing. Biocentriq manufactures immunotherapies, including monoclonal antibodies and proteins, and vaccines and they also offer workforce development programs.
With Generous Support From
Jobs & Contact
Be part of a dynamic and growing team working at the intersection of engineering, biology, and advanced manufacturing. We have several open positions and looking forward to receiving your CV/resume at email@example.com if you are interested in joining us.